A Multicenter, Open-Label, Dose-Escalating Phase I Trial of the DNA-PK Inhibitor MSC2490484A in Subjects With Advanced Solid Tumors or Chronic Lymphocytic Leukemia

Trial Profile

A Multicenter, Open-Label, Dose-Escalating Phase I Trial of the DNA-PK Inhibitor MSC2490484A in Subjects With Advanced Solid Tumors or Chronic Lymphocytic Leukemia

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Nov 2017

At a glance

  • Drugs M 3814 (Primary)
  • Indications Chronic lymphocytic leukaemia; Small cell lung cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Merck KGaA
  • Most Recent Events

    • 25 Oct 2017 Status changed from active, no longer recruiting to completed.
    • 11 Sep 2017 Trial focus has been changed from TU and AR to AR as primary endpoint 'overall response' removed from the study.
    • 21 Aug 2017 Study design changed from Single Group Assignment to Parallel Assignment. Primary endpoint 'overall response' added to the study, hence trail will also assess the therapeutic use of the drug. Also, small-cell-lung-cancer patients included in part B and C, patients with chronic lymphocytic leukemia won't be analysed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top